title: Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy.
abstract: Gabapentin (GBP) is a drug which is frequently used in diabetic neuropathy. Common adverse effects of GBP include drowsiness, dizziness, ataxia, somnolence, and fatigue. Rhabdomyolysis is an extremely rare side effect of GBP. In this report we describe a case of GBP-induced rhabdomyolysis in a 63-year-old diabetic woman. She presented with severe muscle pain in her extremities, fatigue, decreased urine output and urine discoloration within 3 weeks after starting treatment with GBP (900 mg/day) for diabetic neuropathy. Laboratory tests revealed extreme elevations of muscle enzymes, increased creatinine and potassium levels. She required hemodialysis as a result of anuria. Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of GBP resulted in resolution of clinical and biochemical features of rhabdomyolysis.
authors.affiliation: Department of The Second Internal Medicine, Izmir Bozyaka Education and Research Hospital, Turkey. obilgir2001@yahoo.com
authors.forename: Oktay
authors.initials: O
authors.lastname: Bilgir
authors.forename: Mehmet
authors.initials: M
authors.lastname: Calan
authors.forename: Ferda
authors.initials: F
authors.lastname: Bilgir
authors.forename: Levent
authors.initials: L
authors.lastname: Kebapçilar
authors.forename: Arif
authors.initials: A
authors.lastname: Yüksel
authors.forename: Yasar
authors.initials: Y
authors.lastname: Yildiz
authors.forename: Ismail
authors.initials: I
authors.lastname: Sari
mesh_terms: D000588:Amines / Q000009:adverse effects* / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects* / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000201:enzymology; D011188:Potassium / Q000097:blood; D012206:Rhabdomyolysis / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis*; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D003404:Creatinine; D011188:Potassium